PHARMA INFORMATIQUE INVEST - P2I : revenue, balance sheet and financial ratios

PHARMA INFORMATIQUE INVEST - P2I is a French company founded 8 years ago, specialized in the sector Activités des sièges sociaux. Based in PLERIN (22190), this company of category PME shows in 2024 a revenue of 295 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-18

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMA INFORMATIQUE INVEST - P2I (SIREN 830471777)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017
Revenue 295 200 € 215 000 € 215 000 € 192 000 € 192 000 € 192 000 € 161 332 € N/C
Net income 283 633 € 289 907 € 43 405 € -12 528 € -16 047 € -16 310 € 253 666 € 799 421 €
EBITDA 18 814 € -2 304 € 19 710 € 5 688 € 9 145 € 8 337 € 9 215 € -9 491 €
Net margin 96.1% 134.8% 20.2% -6.5% -8.4% -8.5% 157.2% N/C

Revenue and income statement

In 2024, PHARMA INFORMATIQUE INVEST - P2I achieves revenue of 295 k€. Over the period 2018-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +10.6%. Vs 2023, growth of +37% (215 k€ -> 295 k€). After deducting consumption (0 €), gross margin stands at 295 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 19 k€, representing 6.4% of revenue. Positive scissor effect: EBITDA margin improves by +7.4 pts, sign of improved operational efficiency. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 284 k€, i.e. 96.1% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

295 200 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

295 200 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

18 814 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

19 132 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

283 633 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

6.4%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 73%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 57%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 5.6 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 96.1% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

73.429%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

57.074%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

96.082%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

5.585

Solvency indicators evolution
PHARMA INFORMATIQUE INVEST - P2I

Sector positioning

Debt ratio
73.43 2024
2022
2023
2024
Q1: 0.06
Med: 14.64
Q3: 89.5
Average -5 pts over 3 years

In 2024, the debt ratio of PHARMA INFORMATIQUE INVES... (73.43) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
57.07% 2024
2022
2023
2024
Q1: 11.6%
Med: 51.97%
Q3: 85.23%
Good +11 pts over 3 years

In 2024, the financial autonomy of PHARMA INFORMATIQUE INVES... (57.1%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
5.58 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.21 years
Q3: 3.74 years
Average

In 2024, the repayment capacity of PHARMA INFORMATIQUE INVES... (5.58) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 684.88. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 443.1x. Operating income very largely covers interest expenses: high safety margin.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

684.877

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

443.143

Liquidity indicators evolution
PHARMA INFORMATIQUE INVEST - P2I

Sector positioning

Liquidity ratio
684.88 2024
2022
2023
2024
Q1: 116.82
Med: 458.52
Q3: 2178.3
Good

In 2024, the liquidity ratio of PHARMA INFORMATIQUE INVES... (684.88) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Interest coverage
443.14x 2024
2022
2023
2024
Q1: -45.38x
Med: 0.0x
Q3: 2.89x
Excellent

In 2024, the interest coverage of PHARMA INFORMATIQUE INVES... (443.1x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 83 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 256 days. Excellent situation: suppliers finance 173 days of the operating cycle (retail model). Overall, WCR represents 210 days of revenue, i.e. 172 k€ to permanently finance.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

171 860 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

83 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

256 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

210 j

WCR and payment terms evolution
PHARMA INFORMATIQUE INVEST - P2I

Positioning of PHARMA INFORMATIQUE INVEST - P2I in its sector

Comparison with sector Activités des sièges sociaux

Valuation estimate

Based on 103 transactions of similar company sales in 2024, the value of PHARMA INFORMATIQUE INVEST - P2I is estimated at 620 123 € (range 209 280€ - 1 598 144€). With an EBITDA of 18 814€, the sector multiple of 5.0x is applied. The price/revenue ratio is 0.38x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
103 transactions
209k€ 620k€ 1598k€
620 123 € Range: 209 280€ - 1 598 144€
NAF 5 année 2024

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
18 814 € × 5.0x
Estimation 94 659 €
16 295€ - 156 595€
Revenue Multiple 30%
295 200 € × 0.38x
Estimation 111 473 €
53 131€ - 225 137€
Net Income Multiple 20%
283 633 € × 9.5x
Estimation 2 696 760 €
925 968€ - 7 261 529€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 103 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Activités des sièges sociaux)

Compare PHARMA INFORMATIQUE INVEST - P2I with other companies in the same sector:

Voir toutes les statistiques du secteur Activités des sièges sociaux

Frequently asked questions about PHARMA INFORMATIQUE INVEST - P2I

What is the revenue of PHARMA INFORMATIQUE INVEST - P2I ?

The revenue of PHARMA INFORMATIQUE INVEST - P2I in 2024 is 295 k€.

Is PHARMA INFORMATIQUE INVEST - P2I profitable?

Yes, PHARMA INFORMATIQUE INVEST - P2I generated a net profit of 284 k€ in 2024.

Where is the headquarters of PHARMA INFORMATIQUE INVEST - P2I ?

The headquarters of PHARMA INFORMATIQUE INVEST - P2I is located in PLERIN (22190), in the department Cotes-d'Armor.

Where to find the tax return of PHARMA INFORMATIQUE INVEST - P2I ?

The tax return of PHARMA INFORMATIQUE INVEST - P2I is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMA INFORMATIQUE INVEST - P2I operate?

PHARMA INFORMATIQUE INVEST - P2I operates in the sector Activités des sièges sociaux (NAF code 70.10Z). See the 'Sector positioning' section above to compare the company with its competitors.